RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE ...

The PIK3CA wild-type cohort of the Phase 3 VIKTORIA-1 trial is 100% enrolled; expect to report topline data for this cohort in late Q1 2025 or Q2 2025Approximately $264 million in cash, cash ...

USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – USA News Group News Commentary – As many biotech companies within the oncology space begin to roll out their ...

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Friday.

A woman whose cancer has spread to her bones, back, pelvis and neck but has been denied a life-extending drug because she ...

Enliven Therapeutics (ELVN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sam ...

Snow White star Rachel Zegler wished Americans who voted for Donald Trump 'never know peace' after his landslide election ...

Enliven Therapeutics, Inc. ( (ELVN) ) has released its Q3 earnings. Here is a breakdown of the information Enliven Therapeutics, Inc. presented ...

According to a recent article in Biospace ,"The solid tumors market size reached a value of US$ 170.3 Billion in 2023. Looking forward, the market is expected to reach US$ 375.4 Billion by 2034, ...

Q3 2024 Earnings Call Transcript November 13, 2024 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...